January 7, 2020

Dear Representative:

As national stakeholder organizations representing kidney transplant recipients, transplant candidates, and professionals engaged in organ donation and transplantation, we respectively request you cosponsor legislation that would save lives and reduce Medicare spending. H.R. 5534, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019, was introduced by Representatives Kind (D-WI) and Burgess (R-TX) to ensure patients have access to life-saving immunosuppressive medications.

Medicare Part B coverage of immunosuppressive drugs ends 36 months post-transplant for non-aged, non-disabled kidney recipients. Many patients lack affordable coverage when their Medicare ends and are forced to ration or forgo their medications altogether. Some kidney patients do not try to get a transplant due to fear they will have difficulty maintaining access to the immunosuppressive drugs. This legislation will extend Medicare for the purposes of the immunosuppressive medications only, and only if the transplant recipient lacks private or other public coverage for these drugs.

Two cost reports issued by the Department of Health and Human Services in May 2019 anticipate 10-year cost savings to be up to \$300 million. Medicare spends approximately \$90,000 per year on each dialysis patient whereas Medicare expenses for a transplant recipient after the year of transplant is almost \$35,000. Furthermore, Part B immunosuppressive drug spending is only \$2,300 per patient, per year. It is not sound public policy nor cost effective to cover a kidney transplant and then stop immunosuppressive coverage after 36 months. The current Medicare policy is unfair to patients, living donors, and donor families. If the transplant fails, patients resume Medicare eligibility for dialysis or another transplant, adding costs to the Federal government and adding another name to a kidney wait list of 95,000 Americans.

Correcting the current immunosuppressive coverage policy would save lives and reduce the unnecessary costs to Medicare of returning these patients to dialysis and/or re-transplanting patients. For further information or to cosponsor the legislation, please contact Alex Eveland in Rep. Kind's office or Elizabeth Allen in Rep. Burgess's office.

Sincerely,

Alport Syndrome Foundation American Association of Kidney Patients American Kidney Fund American Nephrology Nurses Association American Society of Nephrology American Society of Pediatric Nephrology American Society of Transplantation American Society of Transplant Surgeons

American Transplant Foundation

Association of Organ Procurement Organizations

Dialysis Patient Citizens

Donate Life America

Donate Life - WoMen Encouraging Living Donation

Donor to Donor

Gift of Hope

Home Dialyzors United

Honor the Gift

Improving Renal Outcomes Collaborative

IgA Nephropathy Foundation of America

John Brockington Foundation

Kidney Donor Athletes

LifeGift

Living Kidney Donors Network

NATCO, The Organization for Transplant Professionals

National Kidney Foundation

NephCure Kidney International

New Jersey Sharing Network

OneLegacy

Organ Donation Advocacy Group

Organ Donation & Transplantation Alliance

PKD Foundation

Renal Physicians Association

Renal Support Network

Southwest Transplant Alliance

Texas Kidney Foundation

Transplant First Academy

Transplant Games of America

Transplant Life Foundation

Transplant Recipients International Organization

Transplant Support Organization

United Network for Organ Sharing

Wait List Zero

Washington Region Transplant Community